LA JOLLA, Calif., Nov. 12 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that the Board of Directors has appointed Evelyn Graham as the Company's Chief Executive Officer and as a member of the Company's Board of Directors. Ms. Graham had been serving as the Company's acting Chief Executive Officer since September 1, 2008.
"Ev has done an impressive job as acting CEO in managing the transition of our company and building a platform for the future," said Peter Davis, Chairman of the TorreyPines Board of Directors. "We are delighted that she has agreed to become CEO and a member of the Board at a time when TorreyPines is completing important clinical trials that hold promise for the company's future. With her considerable drug development experience as well as global senior management roles, she has the right mix of skills and experience to successfully lead the Company in meeting its strategic objectives."
"I am excited by this opportunity and look forward to continuing to work with TorreyPines' talented management team and dedicated employees," said Ms. Graham.
Ms. Graham joined TorreyPines in 2004 as Vice President, Development.
She was then promoted to Vice President, Corporate Development in 2005,
Chief Operating Officer in 2006 and acting Chief Executive Officer in
September 2008. Prior to joining TorreyPines Ms. Graham was Executive
Director, Development Operations at Purdue Pharma from 2000 to 2003. From
1998 to 2000, she was Senior Vice President of Business Development at
Ingenix Pharmaceutical Services, a division of UHG, and served as Vice
President of Clinical Operations at Worldwide Clinical Trials, prior to its
acquisition by UHG. Previously, Ms. Graham held positions in oper
|SOURCE TorreyPines Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved